Page 24 - Preclinical Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Queen's University Belfast, Northern Ireland Van Schaeybroeck's AACR poster presentation "Targeting the DNA repair pathway with BOLD-100 in BRAF-mutant colorectal cancer" (Poster# 1183, Session PO.ET04.03 on April 10) highlights the promising research conducted by the Drug Resistance Group at the Patrick G. Johnston Centre for Cancer Research at Queen's University Belfast, which investigated BOLD-100's mechanism-of-action and identified promising treatment combinations in difficult-to-treat BRAF-mutant colorectal cancers. Colon cancer is one of the most frequently diagnosed malignancies in ad...

Press release content from Business Wire. The AP news staff was not involved in its creation. Bayer to Present New Clinical Data in Indolent non-Hodgkin’s Lymphoma and Additional Research on its Oncology Portfolio at AACR Annual Meeting 2021 April 6, 2021 GMT WHIPPANY, N.J.--(BUSINESS WIRE)--Apr 6, 2021-- Bayer will present new research across its oncology portfolio at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, taking place over two weeks on April 10-15 and May 17-21, 2021. The data include an oral presentation in a Clinical Trials Plenary Session on th...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Shattuck Labs Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business ... Shattuck Labs, Inc.March 15, 2021 GMT – Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 – – Dose-escalation data from Phase 1 clinical trial for lead partnered PD-1 checkpoint inhibitor, SL-279252 (PD1-Fc-OX40L), expected in the second half of 2021 – AUSTIN, TX and DURHAM,...

Oscotec Inc. (039200: KOSDAQ), the Korean drug development company, and Beactica Therapeutics AB, the Swedish drug discovery company, today announced a new research development and licensing agreement. Oscotec and Beactica will initially jointly collaborate concerning research and early preclinical development of novel anti-cancer drug candidates arising out of Beactica's LSD1 programme. Oscotec may thereafter opt to take full responsibility for clinical development and commercialization.

Eurocine Vaccines confirms good immunological effect in preclinical study with the chlamydia vaccine candidate Eurocine Vaccines AB ("Eurocine Vaccines") confirms good immunological effect in a preclinical animal study with its chlamydia vaccine candidate. The study confirms that an adapted variant of the vaccine, designed to meet the regulatory requirements for a finished product, is highly immunogenic. The good immunological effect of the tested vaccine surpasses, by a good margin, what in previous studies with our vaccine has provided protection in preclinical models. STOCKHOLM, Sweden, Fe...